Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16(3):259–68. Epub 1992/03/01.
Article
CAS
Google Scholar
Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136–40. Epub 1996/01/09.
Article
CAS
Google Scholar
Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical cancer research: an official journal of the American Association for Cancer Research. 2001;7(12):3862–8. Epub 2001/12/26.
CAS
Google Scholar
Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27(11):1418–28. Epub 2003/10/25.
Article
Google Scholar
Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11(10):3814–20. Epub 2005/05/18.
Article
CAS
Google Scholar
Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012;107(1):137–42. Epub 2012/05/31.
Article
CAS
Google Scholar
Suzuki T, Yamagishi Y, Einama T, Koiwai T, Yamasaki T, Fukumura-Koga M, et al. Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer. Oncology letters. 2020;20(5):193. Epub 2020/09/22.
CAS
PubMed
PubMed Central
Google Scholar
Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50. Epub 2006/10/28.
Article
Google Scholar
Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009;284(6):3739–49. Epub 2008/12/17.
Article
CAS
Google Scholar
Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190–8. Epub 2003/12/17.
Article
CAS
Google Scholar
Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276–82. Epub 2011/07/22.
Article
CAS
Google Scholar